Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PsiOxus raises £22mm through Series B round

Executive Summary

PsiOxus Therapeutics Ltd. (treatments for cancer and cachexia) raised £22mm ($34mm) through its Series B round. New investors SR One and Lundbeckfond Ventures together contributed £11mm, while returning backers Imperial Innovations (lead) and Invesco Perpetual each invested £5.5mm. Proceeds will fund Phase I and II trials of the company’s ColoAd1 oncolytic vaccine for colorectal and other cancers.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies